Literature DB >> 9720840

Intrauterine insemination as first line treatment of unexplained and male factor infertility.

C Keck1, C Gerber-Schäfer, M Breckwoldt.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the efficacy of intrauterine inseminations (IUI) as first line treatment of unexplained or male factor infertility. STUDY
DESIGN: Retrospective analysis of 414 consecutive IUI treatment cycles in 124 couples with unexplained or male factor infertility.
RESULTS: In 414 cycles 25 pregnancies were achieved (6% pregnancy rate per cycle and 20% per couple respectively). 24 healthy babies were born (20 singletons and 2 twins) as a result of our treatment. There was no significant difference in ejaculate parameters of patients who achieved a pregnancy compared with patients who failed to do so. Lowest values at which pregnancies were achieved were 0.8 mill sperm/ml and 11% progressive motility after sperm processing and 8% normal morphology before semen preparation.
CONCLUSION: There is still a place for IUI as first line treatment for couples with unexplained or male factor infertility. Even in patients with moderate impairment of semen quality pregnancy rates up to 20% per couple can be achieved.

Entities:  

Mesh:

Year:  1998        PMID: 9720840     DOI: 10.1016/s0301-2115(98)00067-0

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Impact of semen characteristics on the success of intrauterine insemination.

Authors:  Yulian Zhao; Nikos Vlahos; David Wyncott; Carolina Petrella; Jairo Garcia; Howard Zacur; Edward E Wallach
Journal:  J Assist Reprod Genet       Date:  2004-05       Impact factor: 3.412

2.  Controlled ovarian stimulation should not be preferred for male infertility treated with intrauterine insemination: a retrospective study.

Authors:  Yan Tang; Qian-Dong He; Ting-Ting Zhang; Jing-Jing Wang; Si-Chong Huang; Yun Ye
Journal:  Reprod Biol Endocrinol       Date:  2021-03-19       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.